Back to mobile site

Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN)

December 30, 2024 11:56 AM EST Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $55.00 price target on Dyne Therapeutics (NASDAQ: DYN)The analyst comments "As ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login